[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Cyprus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":757},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,52,86,114,142,166,200,239,270,302,331,365,401,432,466,487,517,542,570,596,620,651,693,714,735],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100653115","the-effect-of-diaphragmatic-breathing-exercises-before-gastroscopy-on-anxiety-fear-and-vital-signs-100653115",false,"NCT07781943","The Effect of Diaphragmatic Breathing Exercises Before Gastroscopy on Anxiety, Fear, and Vital Signs","The Effect of Diaphragmatic Breathing Exercises Performed Prior to Diagnostic Gastroscopy on Anxiety, Fear, and Vital Signs in Adult Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled to undergo diagnostic gastroscopy.\n* Medically eligible for gastroscopy (ASA Physical Status \\\u003C III or suitable according to the institution's sedation protocol).\n* Able to read and understand the study information and questionnaires. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Cardiac, pulmonary, or other clinical conditions for which the attending physician considers breathing exercises inappropriate.\n* Diagnosed anxiety disorder or psychotic disorder.\n* Development of severe dizziness, syncope, severe dyspnea, chest pain, nausea, marked discomfort, or significant breathing irregularity during the breathing intervention.\n* Withdrawal of consent or unwillingness to continue participation.\n* Inability to complete the intervention because of unexpected changes in the timing of the gastroscopy procedure.",true,"ALL","18 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"NA","Gastroscopy, performed as an invasive procedure for the diagnosis and treatment of upper gastrointestinal tract diseases, is often perceived by patients as an unpleasant and frightening experience, leading to anxiety (Hua et al., 2025). The onset of anxiety reduces procedure tolerance and negatively affects patient compliance (Yang et al., 2024). Factors such as pain, fear of complications, loss of control, and inadequate information are frequently cited as contributors to pre-gastroscopy anxiety (Helba, 2024). Anxiety triggers general stress responses-such as tachycardia, hypertension, and respiratory changes-associated with autonomic nervous system activation, and it impacts sedation requirements and cardiopulmonary risks (Liu, 2025). Breathing exercises, a non-pharmacological intervention, are widely recognized in the literature as effective in alleviating anxiety and fostering positive outcomes in patients (Aktaş, 2022; Bulut \\& Karabulut, 2023). Breathing exercises stand out as a safe, low-cost method that modulates autonomic nervous system activity (Herawati et al., 2023). This study examines the effects of diaphragmatic breathing exercises performed prior to gastroscopy on anxiety, fear, and vital signs. The results of this study will establish a scientific foundation for healthcare professionals regarding the clinical application of breathing exercises and contribute to evidence-based practices aimed at reducing pre-gastroscopy anxiety and fear while enhancing personal coping.",[28,29,30,31,32],"Breath Exercise","State Anxiety","Adult Patients","Vital Signs Monitoring","Fear",[34,32,29,35,36,37,38],"Gastroscopy","Vital Signs","Breathing Exercise","endoscopy","GI endoscopy","RECRUITING","2026-08-21",{"date":42,"type":43},"2026-08-24","ACTUAL",{"date":45,"type":43},"2026-07-31",{"date":47,"type":22},"2026-10-30",{"name":49,"class":50},"Eastern Mediterranean University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100610101","phase-3-triton-pn-a-study-to-evaluate-the-efficacy-and-safety-of-nucresiran-in-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy-100610101","NCT07223203","TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)","TRITON-PN","Inclusion Criteria:\n\n* Has documented diagnosis of hATTR-PN\n* Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant\n* Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)\n* Has a Karnofsky Performance Status (KPS) of ≥60%\n\nExclusion Criteria:\n\n* Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study\n* Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis\n* Has a New York Heart Association (NYHA) heart failure classification \\>2\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 upper limit of normal (ULN)\n* Has total bilirubin \\>1.5 ULN\n* Has estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73m\\^2\n* Has other known causes of sensorimotor or autonomic neuropathy","85 Years",{"count":62,"type":22},125,[64],"PHASE3","The purpose of this study is to:\n\n* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed\n* Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels",[67,68],"Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy","hATTR-PN",[70,71,72,73,74],"Polyneuropathy","Amyloidosis","Transthyretin","TTR","RNAi therapeutic","2026-08-12",{"date":77,"type":43},"2026-08-14",{"date":79,"type":43},"2025-12-12",{"date":81,"type":22},"2031-06-12",{"name":83,"class":84},"Alnylam Pharmaceuticals","INDUSTRY",48,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":93,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE",{"count":95,"type":22},7500,"3 Years","OBSERVATIONAL","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[100,101],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[103],"BPH, Registry, LUTS","2026-08-11",{"date":106,"type":43},"2026-08-13",{"date":108,"type":43},"2023-03-13",{"date":110,"type":22},"2028-12",{"name":112,"class":50},"Société Internationale d'Urologie",30,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100478622","elacestrant-for-treating-erher2--breast-cancer-patients-with-ctdna-relapse-treat-ctdna-100478622","NCT05512364","Elacestrant for Treating ER+\u002FHER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","Elacestrant for Treating ER+\u002FHER2- Breast Cancer Patients With ctDNA Relapse","TREAT ctDNA","Inclusion Criteria:\n\n1. ctDNA screening phase:\n\n   Main inclusion criteria:\n\n   • Female (both pre- and postmenopausal) or male patients with histologically confirmed ER positive (regardless of PR),\n\n   HER2 negative breast cancer, according to local pathologist:\n   * ER-positive defined as ≥ 10% of cells staining positive for ER or Allred proportion score ≥3\n   * HER2-negative defined as a score of 0, 1+ by immunohistochemistry (IHC) or a negative in situ hybridization (ISH) based on single-probe average HER2 copy number, as per American Society of Clinical Oncology guidelines\n   * Intermediate to high risk of recurrence after definitive treatment for early breast cancer, defined as:\n\n   FOR PATIENTS TREATED WITH PRIMARY SURGERY:\n   * Any patient with ≥ 4 positive axillary lymph nodes (stage pN2-3).\n   * 1-3 positive axillary lymph nodes (stage pN1) and either:\n   * Tumour size ≥ 5 cm or\u002Fand\n   * Histologic grade 3 or\u002Fand\n   * Ki67≥20% or\u002Fand\n   * High genomic risk defined as Oncotype Dx Recurrence Score \\>=26, Mammaprint high risk, Prosigna score \\>40 or EPclin risk score \\>=4.0.\n   * Negative axillary lymph nodes (stage pN0) and tumour size ≥ 2 cm and either\n   * Histologic grade 3 a or\u002Fand\n   * Ki67≥20% and\u002For\n   * High genomic risk defined as Oncotype Dx Recurrence Score \\>=26, Mammaprint high risk, Prosigna score \\>60 or EPclin risk score \\>=4.0. FOR PATIENTS TREATED WITH NEOADJUVANT\n\n   SYSTEMIC TREATMENT FOLLOWED BY SURGERY:\n   * Patient may have received neoadjuvant endocrine therapy or neoadjuvant chemotherapy provided that:\n   * The initial tumour and\u002For the tumour after surgery meet the criteria above defined for patients treated with primary surgery or the initial tumour was staged as cT4anyN and\n   * There is no pathological complete response, defined as no invasive disease in the breast and axilla (ypT0\u002Fis ypN0).\n   * Age ≥18 years\n   * Patients must have received at least 1 year and up to 7.5 years of ET and planned to continue adjuvant ET during ctDNA screening phase\n   * Previous adjuvant CDK4\u002F6 inhibitor or PARP-inhibitor treatment is allowed provided it is completed\n   * Invasive multicentric \u002F multifocal disease is allowed provided that all the tested foci are ER+ HER2-. A sample from the highest-risk one, according to the investigator decision based on the size and grade, should be sent to Natera to build the patient ctDNA assay.\n   * Available tumour sample from resected or biopsied tissue, with a tumour content of ≥20% (30% preferred) either before or after macro dissection (if performed) and a cell viability of a minimum 100 cells.\n   * Core Needle Biopsies (CNB): recommended minimum of four (4) cores per block\n   * Fine Needle Aspirates (FNA) are not accepted\n   * The following sample types are acceptable:\n   * 6-10 unstained slides (charged and unbaked) of 10μm each (or 12-19 unstained slides at 5 μm each), PLUS one contiguous H\\&E slide. Minimum total tissue thickness must be 60μm OR\n   * FFPE tissue block with 25mm2 minimum surface area\n   * Written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\n   Main exclusion criteria:\n   * Suspected recurrent disease or known conflicts with the inclusion and exclusion criteria for the randomised trial\n   * Prior treatment with any SERD or investigational ER antagonist\n   * Previous history of invasive breast cancer\n   * Previous history of any other malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n   * Previous history of bone marrow and\u002For organ transplant\n   * Bilateral invasive breast cancer\n   * Participation in another clinical study, with the exception of the SURVIVE study and observational (non-interventional) and non-drug intervention clinical studies. Note: patients participating in interventional studies may participate once they enter the follow-up period of the study\n   * Blood transfusion within 3 months prior to registration or during the screening.\n2. Randomised trial:\n\nMain inclusion criteria:\n\n* ctDNA positive according to the Signatera ctDNA assay (main study ctDNA test) or other ctDNA assay approved for diagnostic purposes.\n* Patients must meet the eligibility criteria for the screening phase, with the exception of the tissue sample requirements.\n* Patients must receive adjuvant ET at the time of the ctDNA positive test\n* Absence of locoregional and\u002For metastatic disease and\u002For new malignancy, as investigated by:\n* Mammogram (unilateral in case of mastectomy; not required in patients having undergone bilateral mastectomy) NOTE: if local investigator plans to use MRIs instead of mammograms during the study, MRI will have to be performed at baseline.\n* CT thorax and abdomen\u002Fpelvis with IV contrast. In case of any contra-indications (medical or regulatory): CT thorax without contrast + MRI abdomen\u002Fpelvis.\n* Technetium-99m bone scintigraphy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Adequate organ function\n* Women of childbearing potential (WOCBP) must have a negative highly sensitive serum or urine pregnancy test within 7 days prior to randomisation.\n\nMain exclusion criteria:\n\n* Any unresolved toxic effect of prior therapies or surgical procedures of Grade ≥ 2 according to Common Terminology Criteria of Adverse Events (CTCAE) v5.0, with the exception of alopecia, peripheral neuropathy and other toxicities not considered a safety risk for the participant at investigator's discretion\n* Unable or unwilling to avoid over-the-counter medications, dietary\u002Fherbal supplements, and\u002For foods that are moderate\u002Fstrong inhibitors or inducers of CYP3A4 activity\n* Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications\n* Any of the following cardiovascular disorders within 3 months before enrolment:\n* myocardial infarction\n* stroke\n* severe\u002Funstable angina\n* symptomatic cardiac arrhythmia\n* prolonged QTcF ≥ Grade 3 (i.e., \\> 500 msec)\n* heart failure ≥ Class III as defined by the New York Heart Association (NYHA) guidelines\n* CTCAE version 5.0 grade 3 or 4 dyslipidemia at the time of screening, defined as cholesterol\\>400 mg\u002FdL or \\>10.34 mmol\u002FL and\u002For triglycerides\\>500 mg\u002FdL or \\>5.7 mmol\u002FL.\n* Child-Pugh Score greater than Class A\n* Uncontrolled significant active infections (≥ grade 3 according to CTCAE version 5), including active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency Virus (HIV)\n* Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism",{"count":123,"type":22},220,[64],"This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+\u002FHER2- breast cancer and ctDNA relapse.\n\nDuring the ctDNA screening phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood.\n\nPatients who are found to be ctDNA-positive and have no evidence of distant metastasis, will be randomised 1:1 between standard endocrine treatment (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria. After completion of the protocol treatment period, treatment will be left at the discretion of the treating physician.",[127,128,129,130],"ER-positive Breast Cancer","HER2-negative Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer","2026-08-07",{"date":133,"type":43},"2026-08-10",{"date":135,"type":43},"2023-12-15",{"date":137,"type":22},"2035-11-01",{"name":139,"class":140},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",111,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":152,"studyType":97,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100452271","the-oxford-risk-factors-and-non-invasive-imaging-study-100452271","NCT05169333","The Oxford Risk Factors And Non-Invasive Imaging Study","ORFAN","Inclusion Criteria:\n\nInclusion Criteria for study Arms 1, 2 and 3:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 -99 years.\n\nInclusion Criteria for study Arm 4:\n\n• Male or Female, aged 18 -99 years.\n\nExclusion Criteria:\n\nExclusion Criteria for Study Arms 1, 2 and 3:\n\n* Unable or unwilling to consent\n* Active cancer\n\nExclusion Criteria for Study Arm 4:\n\n* Participation in Study Arms 1, 2 or 3\n* Existing opt-out from use of data for research purposes","99 Years",{"count":151,"type":22},250000,"15 Years","ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.",[155,156],"Cardiovascular Diseases","Cardiovascular Risk Factors","2026-07-30",{"date":45,"type":43},{"date":160,"type":43},"2016-02-23",{"date":162,"type":22},"2030-02",{"name":164,"class":50},"University of Oxford",45,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":51},"100650047","comparison-of-prf-and-corticosteroids-in-impacted-third-molar-surgery-100650047","NCT07742826","Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery","Comparison of Postoperative Effects of PRF and Corticosteroid Treatments in Impacted Third Molar Surgery","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with good general health\n* Patients with complete clinical and radiographic examination (panoramic radiograph\u002FCBCT if applicable)\n* Patients willing and able to attend all postoperative follow-up visits\n\nExclusion Criteria:\n\n* Patients with systemic diseases that may impair wound healing (e.g., uncontrolled diabetes, immunodeficiency).\n* Pregnant or breastfeeding women.\n* Patients with acute infection, abscess, or pericoronitis at the surgical site.\n* Patients with a history of allergy or contraindication to corticosteroids, local anesthetics, or prescribed medications.\n* Patients using corticosteroids, anticoagulants, immunosuppressive drugs, or bisphosphonates.\n* Patients with bleeding disorders.\n* Patients with previous radiotherapy to the head and neck region.\n* Patients unable or unwilling to comply with the study protocol or attend follow-up visits.",{"count":174,"type":22},60,[25],"This prospective, randomized interventional study aims to compare the postoperative effects of standard treatment (control), platelet-rich fibrin (PRF), and PRF combined with corticosteroid treatment in patients undergoing impacted mandibular third molar surgery. A total of 60 participants will be randomly assigned to one of three treatment groups according to the study protocol. Postoperative pain, facial swelling, and trismus will be evaluated on postoperative days 1, 2, 3, and 7. The findings of this study are expected to provide evidence regarding the effectiveness of PRF alone and PRF combined with corticosteroid treatment in reducing postoperative complications following impacted mandibular third molar surgery.",[178,179,180],"Impacted Mandibular Third Molar Extraction","Impacted Lower Third Molar","Impacted Wisdom Tooth",[182,183,184,185,186,187,188,189,190],"Third Molar Surgery","Impacted Third Molar","Platelet-Rich Fibrin","Corticosteroids","Postoperative Pain","Facial Swelling","Trismus","Oral Surgery","Postoperative Complications","2026-07-29",{"date":193,"type":43},"2026-08-03",{"date":195,"type":43},"2024-09-03",{"date":197,"type":22},"2026-08",{"name":199,"class":50},"Final International University",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":211,"conditions":212,"keywords":221,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":51},"100649654","multimodal-assessment-and-prognosis-in-disorders-of-consciousness-after-severe-brain-injury-cydoc-map-100649654","NCT07736820","Multimodal Assessment and Prognosis in Disorders of Consciousness After Severe Brain Injury (CyDoC-MAP)","Cyprus Disorders of Consciousness - Multimodal Assessment and Prognosis Study: A Single-Centre Prospective Observational Cohort Study of Clinical, Biochemical, Electrophysiological and Imaging Predictors of Long-Term Outcome After Severe Traumatic Brain Injury or Haemorrhagic Stroke","CyDoC-MAP","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Age 16 years or older\n* Moderate-to-severe traumatic brain injury, or haemorrhagic stroke (intracerebral or subarachnoid haemorrhage)\n* Intubation for a reduced level of consciousness within 24 hours of the index event\n* Admitted to, or transferred to, Nicosia General Hospital\n* Classified as VS\u002FUWS or MCS on the Coma Recovery Scale-Revised after discharge from the intensive care unit\n* Written informed consent obtained from the next of kin (and from a legal guardian for participants aged 16-17)\n\nExclusion Criteria:\n\n* Severe pre-existing psychiatric disorder\n* History of ischaemic or haemorrhagic stroke\n* Pre-existing dementia\n* Reduction in Glasgow Coma Scale attributable to sedation or intoxicating substances\n* Reduction in Glasgow Coma Scale attributable to severe extracranial injury (massive haemorrhage, generalised hypoxia)\n* End-stage disease with a life expectancy of less than 6 months","16 Years",{"count":210,"type":22},40,"After a severe brain injury some patients survive but cannot communicate, and deciding early which of them are likely to recover consciousness remains one of the hardest problems in neurocritical care. Bedside examination alone misclassifies a substantial proportion of these patients.\n\nCyDoC-MAP is a single-centre, prospective, observational cohort study conducted at Nicosia General Hospital, the sole trauma referral centre for Cyprus. It enrols patients aged 16 years or older who are intubated within 24 hours of a moderate-to-severe traumatic brain injury or a haemorrhagic stroke (intracerebral or subarachnoid haemorrhage), and who are subsequently classified as being in a vegetative state \u002F unresponsive wakefulness syndrome (VS\u002FUWS) or a minimally conscious state (MCS) on the Coma Recovery Scale-Revised (CRS-R).\n\nFour assessment modalities are recorded: (1) the CRS-R, performed at least twice with an interval of at least 48 hours; (2) serum neuron-specific enolase (NSE) sampled within 24 hours of intubation; (3) the bispectral index (BIS), recorded at least twice with an interval of at least 48 hours, after five minutes of standardised noxious and auditory stimulation; and (4) in the traumatic subgroup only, 1.5 T magnetic resonance imaging performed 7-28 days after injury and graded 1-4 by lesion depth by two independent raters.\n\nLevel of consciousness is reassessed with the CRS-R 6 to 12 months after the index event, and the total CRS-R score (0-23) at that reassessment is the primary outcome. The primary aim is to estimate the strength of the association between the bispectral index recorded on the ward and that later CRS-R score, and to quantify what the bispectral index adds beyond the baseline clinical assessment. The number of eligible patients at a single national centre does not support the development of a prognostic model; the study is designed to produce effect-size estimates with confidence intervals that will inform a subsequent multicentre study.\n\nThe study is purely observational. No intervention is administered, no study procedure alters clinical management, and transfer to rehabilitation is never delayed for research purposes.",[213,214,215,216,217,218,219,220],"Consciousness Disorders","Persistent Vegetative State","Unresponsive Wakefulness Syndrome","Minimally Conscious State","Coma; Prolonged","Brain Injuries, Traumatic","Cerebral Hemorrhage","Subarachnoid Hemorrhage",[222,223,224,225,226,227,228,229],"cognitive motor dissociation","covert consciousness","Coma Recovery Scale-Revised","bispectral index","neuron-specific enolase","multimodal prognostication","neurocritical care","Cyprus","NOT_YET_RECRUITING","2026-07-27",{"date":157,"type":43},{"date":234,"type":22},"2026-09-15",{"date":236,"type":22},"2030-09-30",{"name":238,"class":50},"Nicosia General Hospital",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100642817","turkish-version-of-the-ankle-fracture-outcome-of-rehabilitation-measure-a-form-tr-a-multi-centre-validation-study-100642817","NCT07620015","Turkish Version of the Ankle Fracture Outcome of Rehabilitation Measure (A-FORM-TR): A Multi-Centre Validation Study","Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of the Ankle Fracture Outcome of Rehabilitation Measure (A-FORM-TR): A Multi-Centre Prospective Observational Study","A-FORM-TR","Inclusion Criteria:\n\n* Age 18 years or older\n* Radiographically confirmed unilateral ankle fracture (Weber A, B, or C)\n* Either surgical (open reduction and internal fixation) or conservative (cast, walker boot, or functional brace) treatment completed\n* Currently in the rehabilitation phase, 3 weeks to 12 months post-injury\n* Native Turkish speaker, able to read and self-complete a questionnaire\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Bilateral ankle fracture\n* Previous ipsilateral ankle fracture or any prior orthopedic surgery on the same ankle\n* Pathological fracture (tumour, metastasis, or other underlying bone pathology)\n* Concurrent significant ipsilateral lower-limb injury (for example pilon fracture, ipsilateral tibial or fibular shaft fracture, ipsilateral femoral or tibial plateau fracture)\n* Polytrauma (significant head, spine, abdominal, or contralateral lower-limb injury affecting function)\n* Cognitive or psychiatric impairment precluding self-completion of the questionnaire\n* Insufficient Turkish literacy\n* Inability to attend a follow-up visit for the test-retest assessment",{"count":248,"type":22},150,"Ankle fractures are common injuries that can affect a patient's mobility, mood, sleep, and everyday life for months. The Ankle Fracture Outcome of Rehabilitation Measure (A-FORM) is an English-language patient-reported outcome measure developed in Australia to capture this broader rehabilitation experience. No validated Turkish version of A-FORM currently exists. This prospective multi-centre observational study aims to translate the A-FORM into Turkish (A-FORM-TR), culturally adapt it for use in Turkish-speaking patients, and evaluate its psychometric properties. The investigators will recruit 150 adults with a unilateral ankle fracture, treated either surgically or conservatively, from three orthopedic centres in Turkiye and the Turkish Republic of Northern Cyprus. Participants complete the A-FORM-TR together with two established comparator questionnaires (AOFAS Ankle-Hindfoot Score and the Turkish Olerud-Molander Ankle Score). A subset of approximately 50 participants is re-administered the A-FORM-TR after 7 to 14 days to assess test-retest reliability, with a Global Rating of Change item identifying clinically stable patients. Analyses include classical test theory, confirmatory factor analysis, and Rasch measurement analysis.",[251,252],"Ankle Fractures","Ankle Injuries",[254,255,256,257,258,259,260,261],"patient-reported outcome measure","PROM","cross-cultural adaptation","psychometric validation","ankle fracture","rehabilitation","Rasch analysis","Turkish","2026-07-24",{"date":231,"type":43},{"date":262,"type":43},{"date":266,"type":22},"2027-07",{"name":268,"class":50},"Utku Gürhan",3,{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":51},"100645479","effects-of-different-myofascial-release-techniques-on-function-in-chronic-non-specific-neck-pain-100645479","NCT07694882","Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain","Investigation of the Effects of Different Myofascial Release Techniques on Functional Outcomes in Individuals With Chronic Non-Specific Neck Pain","MFR \u002F CNNP","Inclusion Criteria:\n\n* Neck pain persisting for at least 3 months and diagnosed as chronic non-specific neck pain by a specialist physician\n* Aged between 18 and 45 years\n* Perceived pain affecting daily living activities (VAS at least 3)\n* Presence of myofascial trigger points in the upper-quarter muscles\n\nExclusion Criteria:\n\n* Specific serious cervical spine pathology (radiculopathy, myelopathy, severe nerve root compression, spondylosis, and similar)\n* History of rheumatologic, neurologic, or systemic disease (for example, acute inflammation, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, fibromyalgia, or cancer)\n* History of trauma, fracture, or surgery involving the neck, shoulder, or upper extremity\n* Pregnancy or breastfeeding\n* Any diagnosed psychiatric disorder (for example, major depression or anxiety disorder) or regular use of psychopharmacological medication\n* Use of systemic analgesics, NSAIDs, or muscle relaxants within the last 7 days for pain control\n* Any physiotherapy, manual therapy, or injection treatment to the neck region within the last 3 months","45 Years",{"count":280,"type":22},84,[25],"This single-center, three-arm randomized controlled trial compares the effects of different myofascial release techniques, combined with a structured exercise program, on functional outcomes in individuals with chronic non-specific neck pain (CNNP).\n\nEligible participants (aged 18 to 45 years, neck pain for at least 3 months, pain intensity VAS at least 3, and myofascial trigger points in the upper-quarter muscles) are allocated by simple randomization into three groups:\n\n* Conventional Therapy Group: hot pack, conventional TENS, and a structured exercise program.\n* Manual Myofascial Release Group: conventional therapy plus therapist-applied manual myofascial release.\n* Self-Myofascial Release Group: conventional therapy plus supervised self-applied myofascial release using a duo-ball, balls, and a massage stick\u002Fcane.\n\nAll interventions are delivered 3 days per week for 6 weeks. The primary outcome is pain intensity. Secondary outcomes include pressure pain threshold and tolerance, cervical range of motion, muscle stiffness, craniovertebral angle, cervical proprioception, muscle strength and endurance, disability, neck awareness, multidimensional biopsychosocial status, sleep quality, quality of life, and kinesiophobia. The aim is to determine whether manual or self-applied myofascial release, added to exercise, produces greater functional improvement in people with chronic non-specific neck pain.",[284,285,286,287],"Chronic Neck Pain","Non-specific Neck Pain","Myofascial Trigger Points","Myofascial Pain Syndrome - Neck",[289,290,291,292,293,294],"chronic non-specific neck pain","myofascial release","manual therapy","trigger points","therapeutic exercise","physiotherapy","2026-07-13",{"date":297,"type":43},"2026-07-14",{"date":297,"type":43},{"date":300,"type":22},"2026-12-31",{"name":49,"class":50},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":309,"maxAge":4,"enrollmentInfo":310,"targetDuration":312,"studyType":97,"phases":4,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":330},"100273106","specta-screening-cancer-patients-for-efficient-clinical-trial-access-100273106","NCT02834884","SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access","SPECTA","* Patients with pathologically confirmed selected tumor types (at site or centrally);\n* Mandatory availability of adequate human biological material (HBM);\n* Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;\n* Age ≥ 12 years;\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;\n* Written informed consent according to applicable legal and ethical requirements;","12 Years",{"count":311,"type":22},4975,"5 Years","SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.",[315],"All Tumor Types",[317,318,319,320,321],"rare cancer","biomarker","molecular screening","cancer","biobanking","2026-06-19",{"date":324,"type":43},"2026-06-24",{"date":326,"type":43},"2017-05-03",{"date":328,"type":22},"2031-10",{"name":139,"class":140},136,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":51},"100638384","blood-cell-ratios-as-predictors-of-response-to-platelet-rich-plasma-in-knee-osteoarthritis-100638384","NCT07617233","Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis","Baseline Neutrophil-to-Lymphocyte Ratio and Related Complete Blood Count-Derived Inflammatory Indices as Predictors of Clinical Response to Intra-Articular Platelet-Rich Plasma in Knee Osteoarthritis: A Prospective Single-Arm Cohort Study","PRP-NLR","Inclusion Criteria:\n\n* Age 40 to 60 years\n* Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs\n* Body mass index below 40\n* Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee\n* Able and willing to provide written informed consent and to attend the 6-month follow-up schedule\n\nExclusion Criteria:\n\n* Systemic inflammatory or autoimmune disease\n* Active acute infection at the time of enrollment\n* Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy\n* Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations\n* Intra-articular injection of the index knee within the previous 6 months\n* Inability to comply with the planned follow-up schedule","40 Years","60 Years",{"count":342,"type":22},120,"Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.",[345,346],"Knee Osteoarthritis","Osteoarthritis",[348,349,350,351,352,353,318,354,355,356,357],"platelet-rich plasma","PRP","knee osteoarthritis","neutrophil-to-lymphocyte ratio","NLR","systemic immune-inflammation index","predictor","intra-articular injection","WOMAC","inflammatory index","2026-06-18",{"date":360,"type":43},"2026-06-23",{"date":362,"type":22},"2026-09",{"date":266,"type":22},{"name":268,"class":50},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":375,"conditions":376,"keywords":381,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100641416","patient-ai-trust-dynamics-before-and-after-orthopedic-consultation-ortho-op-gpt-100641416","NCT07631585","Patient AI Trust Dynamics Before and After Orthopedic Consultation (ORTHO-OP-GPT)","Longitudinal Pre-Post Patient AI Trust Dynamics in Orthopedic Outpatients: A Mixed-Methods Observational Study With Matched Physician-Patient Dyads","ORTHO-OP-GPT","Inclusion Criteria:\n\n* Age 18 years or older\n* Presenting to an orthopedic outpatient clinic for any consultation\n* Able to read and respond to a Turkish-language questionnaire\n* Provides informed consent\n\nExclusion Criteria:\n\n* Inability to complete a self-report questionnaire (e.g., severe cognitive impairment, language barrier)\n* Re-presentation within the same recruitment window (each patient is enrolled only once)\n* Refusal of consent for either T0 or T1",{"count":374,"type":22},180,"Patients increasingly consult artificial intelligence (AI) chatbots such as ChatGPT for health information before clinical visits, yet the impact of an actual orthopedic consultation on patient trust in AI-derived information remains unknown. This prospective longitudinal observational study quantifies how a single orthopedic outpatient consultation modifies patient trust in AI chatbots, the concordance between AI-derived and physician-delivered information, and patient anxiety, using a paired pre-post survey design supplemented by a matched physician-side assessment. Adult patients (18 years and older) presenting to two orthopedic outpatient clinics in Cyprus complete a brief pre-consultation questionnaire (T0) capturing demographics, AI use patterns, prior AI consultation regarding the current complaint, baseline trust, expectations, and anxiety. Immediately after their consultation they complete a second questionnaire (T1) assessing concordance with physician advice, trust change, consultation facilitation, post-consultation anxiety, and future intention. The consulting physician completes a brief 30-second post-visit form capturing whether AI was discussed, the medical accuracy of AI-derived information conveyed by the patient, and the effect of the AI discussion on consultation duration. The primary outcomes are the paired within-patient change in AI trust between T0 and T1 and physician-patient concordance on AI versus physician advice. Target enrollment is 180 to obtain 150 paired completed assessments.",[377,378,379,380],"Patient Health Information Seeking Behavior","Trust","Health Literacy","Orthopedics",[382,383,384,385,386,387,388,389,390,391],"ChatGPT","large language model","artificial intelligence chatbot","patient education","health information seeking","trust","physician-patient communication","orthopedics","cross-sectional","pre-post","2026-06-14",{"date":394,"type":43},"2026-06-17",{"date":396,"type":22},"2026-06",{"date":398,"type":22},"2027-01",{"name":268,"class":50},2,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":413,"conditions":414,"keywords":418,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":400},"100635047","phase-4-prp-vs-prpbetamethasone-vs-betamethasone-injection-for-upper-trapezius-myofascial-pain-100635047","NCT07547605","PRP vs PRP+Betamethasone vs Betamethasone Injection for Upper Trapezius Myofascial Pain","Comparison of Platelet-Rich Plasma, Combined Platelet-Rich Plasma Plus Betamethasone, and Betamethasone Monotherapy Trigger Point Injections in Patients With Upper Trapezius Myofascial Pain Syndrome: A Prospective, Randomized, Assessor-Blind, Controlled Trial","UMAY-RCT","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Presentation to the Orthopedics and Traumatology outpatient clinic with neck and\u002For shoulder pain\n* Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including:\n* Presence of a taut band\n* Local tenderness\n* Referred pain pattern\n* Local twitch response\n* Presence of a single active trigger point in the upper trapezius muscle\n* Symptom duration ≥ 4 weeks\n* Pain intensity ≥ 4 on the visual analog scale (VAS)\n* Inadequate response to at least 4 weeks of conservative treatment (physical therapy and\u002For oral analgesics)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of multiple active trigger points\n* Diagnosis of fibromyalgia according to ACR 2010 criteria\n* Cervical radiculopathy or myelopathy\n* Trigger point injection in the same region within the past 3 months\n* Coagulopathy or current anticoagulant or antiplatelet therapy\n* Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components\n* Active infection (systemic or local)\n* Pregnancy or lactation\n* Thrombocytopenia (platelet count \\\u003C 100,000\u002FµL)\n* Malignancy\n* Inability to cooperate or provide informed consent","65 Years",{"count":248,"type":22},[412],"PHASE4","Brief Summary\n\nMyofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger points (TrPs), which are hypersensitive, painful nodules within taut bands of skeletal muscle. The upper trapezius muscle is one of the most frequently affected sites. Trigger point injection (TPI) is a widely used minimally invasive treatment for patients who are refractory to conservative management.\n\nCorticosteroids provide rapid anti-inflammatory effects, whereas platelet-rich plasma (PRP) has regenerative properties through growth factors that may support tissue healing. Despite their widespread use, the optimal injectate for TPI remains unclear. Additionally, the potential benefit of combining PRP with corticosteroids has not been adequately studied in upper trapezius MPS.\n\nThis study is a single-center, prospective, randomized, assessor-blinded controlled trial designed to compare the clinical effectiveness of three injection protocols: (1) PRP plus bupivacaine, (2) PRP plus betamethasone plus bupivacaine, and (3) betamethasone plus bupivacaine with saline (volume-matched control). A total of 150 patients with a single active trigger point in the upper trapezius will be included.\n\nThe primary outcome is pain intensity measured by the visual analog scale (VAS) at 3 months. Secondary outcomes include pressure pain threshold (PPT), cervical range of motion (ROM), rescue analgesic use, recurrence rate, and adverse events at 1 week, 4 weeks, 3 months, and 6 months.\n\nAll injections are performed by the same investigator using a palpation-guided technique, and outcome assessments are conducted by a blinded evaluator.",[415,416,417],"Myofascial Pain Dysfunction Syndrome","Trigger Points, Myofascial","Trigger Point in Trapezius Muscle",[348,349,419,420,421,422,423,424],"betamethasone","trigger point injection","myofascial pain syndrome","trapezius","randomized controlled trial","pressure pain threshold",{"date":426,"type":43},"2026-06-16",{"date":428,"type":43},"2026-05-15",{"date":398,"type":22},{"name":431,"class":50},"University of Kyrenia",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":442,"conditions":443,"keywords":449,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":51},"100643224","mitophagy-and-mitochondrial-dna-dynamics-during-ramadan-dry-fasting-vs-168-time-restricted-feeding-100643224","NCT07638696","Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding","Mitophagic Flux and Mitochondrial DNA Dynamics During Circadian-Aligned Ramadan Dry Fasting Versus 16:8 Time-Restricted Feeding: A Four-Phase Translational Research Programme","MITO FAST","Inclusion Criteria:\n\n* Common Criteria (Both Arms):\n* Age 18-50 years\n* BMI 18.5-30.0 kg\u002Fm²\\[cite: 1\\]\n* Non-smoker for at least 12 months\\[cite: 1\\]\n* No chronic disease requiring regular prescription medication\\[cite: 1\\]\n* Stable sleep-wake schedule (self-reported sleep midpoint deviation less than 90 minutes)\\[cite: 1\\]\n* Willing and able to attend all five study visits at the specified times\\[cite: 1\\]\n\nArm A Specific (Ramadan Dry Fasting):\n\n\\- Documented religious commitment and intention to complete all 30 days of Ramadan 2027 fasting\\[cite: 1\\]\n\nArm B Specific (16:8 TRF Control):\n\n* Confirmed practice of 16:8 TRF (fasting window 16 hours or more per day) throughout the study period\\[cite: 1\\]\n* Not observing Ramadan dry fasting during the study period\\[cite: 1\\]\n\nExclusion Criteria:\n\n* Established type 1 or type 2 diabetes (HbA1c 6.5% or higher or pharmacological antidiabetic therapy)\\[cite: 1\\]\n* Severe gastrointestinal, cardiovascular, hepatic, or renal disease (eGFR less than 60 mL\u002Fmin\u002F1.73m²)\\[cite: 1\\]\n* Active cancer or chemotherapy within five years\\[cite: 1\\]\n* Use of metformin, statins, or exogenous antioxidant supplements (vitamins C, E, NAC, CoQ10) within 30 days of screening\\[cite: 1\\]\n* Pregnancy, lactation, or planned conception during the study period\\[cite: 1\\]\n* Participation in another clinical study within three months\\[cite: 1\\]\n* Inability to provide written informed consent in Arabic or English\\[cite: 1\\]","50 Years",{"count":342,"type":22},"This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset.\n\nResearchers want to see if the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process (called mitophagy) compared to standard 16:8 water-permitted fasting. The study will look at how these fasting habits change blood markers related to mitochondrial DNA and metabolic health across a 30-day period. This research will help determine if dry fasting offers distinct biological benefits for cellular renewal.",[444,445,446,447,448],"Mitochondrial Degradation","Autophagy","Fasting","Healthy Volunteers","Metabolic Adaptation",[450,451,452,453,454,455,456],"Ramadan fasting","Intermittent dry fasting","Time-restricted feeding","Mitochondrial DNA","Mitophagy","PBMC","PINK1-Parkin","2026-06-09",{"date":459,"type":43},"2026-06-11",{"date":461,"type":22},"2027-01-15",{"date":463,"type":22},"2027-04-30",{"name":465,"class":50},"Bahcesehir Cyprus University",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":472,"targetDuration":312,"studyType":97,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":486},"100472368","blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-international-registry-100472368","NCT05430971","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry","Inclusion Criteria:\n\n* Diagnosis of BPDCN\n* Signed informed consent form for prospective patients\n\nExclusion Criteria:\n\n\\-",{"count":473,"type":22},200,"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.",[476],"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","2026-06-04",{"date":479,"type":43},"2026-06-05",{"date":481,"type":43},"2022-07-01",{"date":483,"type":22},"2032-07",{"name":485,"class":50},"Immune Oncology Research Institute",22,{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":409,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":400},"100639405","mitigation-of-health-effects-in-older-adults-with-hypertension-by-reducing-exposure-to-heat-and-air-pollution-100639405","NCT07606859","Mitigation of Health Effects in Older Adults With Hypertension by Reducing Exposure to Heat and Air Pollution","Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks and Enhancing Health systeM Resilience","ISMED CLIM OH","Inclusion Criteria:\n\n* Aged ≥65 years\n* Living in Barcelona (Spain) or Nicosia (Cyprus) metropolitan areas\n* Have a physician's diagnosis of arterial hypertension\n* Receive daily anti-hypertensive medication\n* Clinically stable\n\nExclusion Criteria:\n\n* Currently smoking\n* Presence of any smoking residents in the household\n* Not residing at the household for at least 5 days a week\n* Planning to move from the current home within the next two months\n* No access to Wi-Fi or 4G\u002F5G mobile phone\n* Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, diabetes mellitus type 2 (DM2), inflammatory diseases, renal failure, or active cancer)\n* Illicit drugs abuse\n* Alcohol abuse\n* Psychiatric disorders\n* Severe mental disability that interferes with answering questions or following instructions",{"count":496,"type":22},102,[25],"The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in older adults with hypertension.\n\nThe main questions it aims to answer are:\n\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?\n* Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?\n* Does the intervention (combination of behavioral recommendations for heat mitigation) improve the abnormalities in circadian blood pressure variation experienced by older adults with hypertension, assessed using advanced actigraphy? Researchers will compare measurements between older adults with hypertension carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups.\n\nParticipants will:\n\n* Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months\n* Have their core temperature measured using an eCelsius medical capsule in three repeated assessments\n* Have their blood pressure, oxygen saturation, ECG and heart rate variability measured using 24-hour advanced actigraphy in three repeated assessments\n* Provide samples of urine and blood biomarkers in three repeated assessments.",[500,501],"Hypertension Arterial","65 Years Older",[503,504,505,506,507,508],"Hypertension","Adults 65 years and older","Intervention","Personal Ambient Temperature Exposure","Indoor air quality","Indoor air purification","2026-06-03",{"date":479,"type":43},{"date":512,"type":43},"2026-05-01",{"date":514,"type":22},"2027-07-31",{"name":516,"class":50},"University of Cyprus",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":17,"sex":525,"minAge":526,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":540,"leadSponsor":541,"locationsCount":269},"100638347","mitigation-of-health-effects-in-pregnant-women-by-reducing-exposure-to-heat-and-air-pollution-100638347","NCT07609433","Mitigation of Health Effects in Pregnant Women by Reducing Exposure to Heat and Air Pollution","Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks and Enhancing Health systeM Resilience in Pregnant Women","ISMED CLIM PW","Inclusion Criteria:\n\n* Pregnant Women (PW) aged 20 to 35 years\n* being in the 2nd trimester of a singleton pregnancy (15th-27th week of gestation)\n* Living in Catania (Italy) or Limassol (Cyprus) districts\n* Clinically healthy\n* No Gestational diabetes\n* No pre-eclampsia\n* No severe pregnancy complications\n\nExclusion Criteria:\n\n* Currently smoking\n* Presence of any smoking residents in the household\n* Not residing at the household for at least 5 days a week\n* Planning to move from the current home within the next two months\n* No access to Wi-Fi or 4G\u002F5G mobile phone\n* Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, DM2, inflammatory diseases, renal failure, or active cancer)\n* Drugs abuse\n* Alcohol abuse\n* Psychiatric disorders\n* Severe mental disability that interferes with answering questions or following instructions","FEMALE","20 Years","35 Years",{"count":496,"type":22},[25],"The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in pregnant women.\n\nThe main questions it aims to answer are:\n\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?\n* Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce sleep difficulties experienced by pregnant women, measured using the Pittsburgh Sleep Quality Index?\n\nResearchers will compare measurements between pregnant women carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups.\n\nParticipants will:\n\n* Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months\n* Have their core temperature measured using an eCelsius medical capsule in three repeated assessments\n* Complete the Pittsburgh Sleep Quality Index questionnaire in three repeated assessments\n* Provide samples of urine and blood biomarkers in three repeated assessments.",[532],"Sleep Quality",[534,535,536,537],"Pregnancy","intervention","Sleep quality","personal ambient temperature exposure",{"date":479,"type":43},{"date":512,"type":43},{"date":514,"type":22},{"name":516,"class":50},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":550,"enrollmentInfo":551,"targetDuration":4,"studyType":23,"phases":553,"briefSummary":554,"conditions":555,"keywords":559,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":569},"100640554","mindfulness-meditation-in-hemodialysis-patients-100640554","NCT07620990","Mindfulness Meditation in Hemodialysis Patients","The Effect of Mindfulness Meditation on Sleep, Stress, and Symptoms in Hemodialysis Patients: A Randomized Controlled Trial","MIND-HD","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years\n* Patients receiving hemodialysis treatment for at least 3 months\n* Patients with cognitive functions suitable for the intervention (dementia score ≥21)\n* Patient without hearing, vision or communication problems\n* Patients without a psychiatric diagnosis\n* Patients able to use a smartphone or tablet\n* Patients not participating in another study\n* Patients not using sleep medication or antipsychotic drugs\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 75 years\n* Patients receiving hemodialysis treatment for less than 3 months\n* Patients with cognitive impairment unsuitable for the intervention (dementia score ≤21)\n* Patient with hearing, vision or communication disabilities\n* Patients diagnosed with psychiatric disorders\n* Patients unable to use a smartphone or tablet\n* Patients participating in another study\n* Patients using sleep medication or antipsychotic drugs","75 Years",{"count":552,"type":22},50,[25],"This randomised controlled study aims to evaluate the effects of mindfulness meditation on sleep quality, perceived stress and symptoms levels ion hemodialysis patients. Participants in the intervention group will receive a 4 week mindfulness meditation program in addition to routine care. Outcomes will be assessed before and after the intervention using validated measurement tools.",[556,557,532,558],"Hemodialysis","Stress","Symptom",[560,556,532,557,558],"Mindfulness Meditation","2026-06-01",{"date":563,"type":43},"2026-06-02",{"date":565,"type":43},"2026-04-15",{"date":197,"type":22},{"name":568,"class":50},"Cyprus Aydin University",4,{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":585,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":594,"leadSponsor":595,"locationsCount":400},"100635889","vr-vs-classical-anatomy-teaching-100635889","NCT07558551","VR vs Classical Anatomy Teaching","Comparison of PlayStation VR2-Based Virtual Reality vs. Classical Method in Teaching Wrist Anatomy: A Randomized Controlled Study","VrISt","Inclusion Criteria:\n\n* First-year medical student at Kyrenia University\n* Age ≥ 18 years\n* Voluntary participation\n* Signed written informed consent\n\nExclusion Criteria:\n\n* First-year medical student at Kyrenia University\n* Age ≥ 18 years\n* Voluntary participation\n* Signed written informed consent",{"count":579,"type":22},80,[25],"This is a prospective, single-center, randomized controlled educational trial comparing the effectiveness of PlayStation VR2-based immersive virtual reality (VR) anatomy teaching versus classical (lecture\u002Fatlas\u002F3D-model) teaching for wrist anatomy among first-year medical students at Kyrenia University Dr. Suat Gunsel Hospital. Eighty healthy adult students will be randomized 1:1 into a VR Group (30-35-minute PSVR2 wrist anatomy module delivered on PlayStation 5) or a Classical Group (30-35-minute faculty-led standard anatomy education using lecture, atlas, and 3D anatomical models). The primary outcome is immediate post-test knowledge score (multiple-choice questions plus visual labeling; 0-30 scale). Secondary outcomes include a 2-4-week retention test, Likert-type learning satisfaction (15-75), cognitive load (0-10), and incidence and severity of VR-related side effects (dizziness, nausea, eye strain; 0-3 ordinal). Outcome assessors are blinded to allocation. The study aims to evaluate whether immersive VR is non-inferior or superior to classical teaching for initial acquisition and short-term retention of wrist anatomy knowledge, while characterizing tolerability of consumer-grade VR in an educational setting.",[583,584],"Medical Education","Anatomy Education",[586,587,588,589],"virtual reality","anatomy education","medical students","wrist anatomy","2026-05-20",{"date":592,"type":43},"2026-05-26",{"date":428,"type":43},{"date":197,"type":22},{"name":431,"class":50},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":619},"100364933","phase-3-surgery-with-or-without-neoadjuvant-chemotherapy-in-high-risk-retroperitoneal-sarcoma-100364933","NCT04031677","Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)","STRASS2","1. STRASS 2\n\n   Inclusion Criteria:\n   * Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.\n   * LMS:\n\n     * Any grade LMS can be included\n     * Minimum size of LMS tumor should be 5 cm\n   * LPS:\n\n     * Diagnosis should be confirmed based on MDM2 (Mouse double minute 2 homolog) and CDK4 (Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while proof of MDM2 amplification is highly recommended.\n     * All grade 3 DDLPS can be included.\n     * DDLPS with confirmed grade 2 on biopsy can be included when:\n\n       * The grade 2 DDLPS has an FNCLCC score=5 (Fédération Nationale des Centres de Lutte Contre Le Cancer), and clear necrosis on imaging (whether or not present on the biopsy).\n       * The tumors carry a high risk gene profile as determined by the Complexity INdex in SARComas (CINSARC-high)\n     * Unifocal tumour\n     * Resectable tumour: resectability is based on pre-operative imaging (CT-abdomen, potentially also with MRI) and has to be defined by the local treating sarcoma team. A patient is not considered resectable when the expectation is that only an R2 resection is feasible.\n     * Criteria for non-resectability are:\n     * Involvement of the superior mesenteric artery, aorta, coeliac trunk and\u002For portal vein\n     * Involvement of bone\n     * Growth into the spinal canal\n     * Progression of retro-hepatic inferior vena cava leiomyosarcoma towards the right atrium\n     * Infiltration of multiple major organs like liver, pancreas and or major vessels\n     * Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging. CT thorax abdomen pelvis with IV contrast is the preferred imaging modality. In case of any contra-indications (medical or regulatory), it is allowed to perform a non-contrast CT thorax + MRI abdomen \\& pelvis\n     * Collection of tumour tissue for central pathology review is mandatory.\n     * For patients with LMS: if there is not enough tissue for assessing the grading, this is acceptable.\n     * If tumour tissue is not available for the central pathology review, patient will not be eligible.\n     * If the biopsy was not done or the FFPE of the biopsy not available but at least 10 unstained slides or one pathological block are available for the central review, that will be considered as acceptable.\n     * For the biopsy if fine needle aspiration (FNA) is performed instead of core needle biopsy (CNB) recommended by the standard guidelines, please contact the EORTC medical monitors for further evaluation.\n     * Collection of tumour tissue and blood samples for translational research is mandatory.\n     * In case there is not enough tissue for TR, a new biopsy is not required and if the patient fulfils all other eligibility criteria, he\u002Fshe will be eligible.\n     * If the blood samples are not collected, patient will not be eligible.\n     * If the patient refuses the collection of biomaterial for TR, patient will not be eligible even if he\u002Fshe fulfils all other eligibility criteria\n     * ≥ 18 years old (no upper age limit)\n     * WHO performance status ≤ 2\n     * Adequate haematological and organ function\n     * American Society of Anaesthesiologist (ASA) score \\\u003C 3\n     * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to randomization.\n\n   Note: a woman is considered of childbearing potential, i.e., fertile, if she is following menarche. She remains of childbearing potential until she becomes post-menopausal or permanently sterile.Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n\n   A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 consecutive months without menses, a single FSH measurement is insufficient.\n   * WOCBP in both arms should use highly effective birth control measures, during the study treatment period and for at least 6 months after the last dose of chemotherapy or date of surgery (except for women receiving chemotherapy with ifosfamide who should continue contraception until 1 year after last day of treatment). A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.\n   * For men in the experimental arm: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.\n   * Female subjects who are breast feeding should discontinue nursing prior to the first day of study treatment and until 6months after the last study treatment.\n   * Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\n   Exclusion criteria:\n   * Sarcoma originating from bone structure, abdominal or gynecological viscera\n   * Extension through the sciatic notch or across the diaphragm\n   * Metastatic disease\n   * Any previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy for the present tumour\n   * Hypersensitivity to doxorubicin, ifosfamide, dacarbazine or to any of their metabolites or to any of their excipients\n   * Congestive heart failure\n   * Angina pectoris\n   * Myocardial infarction within 1 year before randomization\n   * Uncontrolled arterial hypertension defined as blood pressure ≥ 150\u002F100 mm Hg despite optimal medical therapy.\n\n   Note: in case of high blood pressure: 1) initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; 2) blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour. The mean SBP \u002F DBP values from each blood pressure assessment must be ≤ 150\u002F90mmHg in order for a patient to be eligible for the study.\n   * Uncontrolled cardiac arrhythmia\n   * Previous treatment with maximum cumulative doses (450mg\u002Fm² Doxorubicin or equivalent 900mg\u002Fm² Epirubicin) of doxorubicin, daunorubicin, epirubicin, idarubicin, and\u002For other anthracyclines and anthracenediones\n   * Active and uncontrolled infections\n   * Vaccination with live vaccines within 30 days prior to study entry\n   * Inflammation of the urinary bladder (interstitial cystitis) and\u002For obstructions of the urine flow.\n   * Other invasive malignancy within 5 years, with the exception of adequately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤ 6prostate cancer.\n   * Uncontrolled severe illness, infection, medical condition (including uncontrolled diabetes), other than the primary LPS or LMS of the retroperitoneum.\n   * Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control method.\n   * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial\n   * Known contraindication to imaging tracer and to MRI\n2. Selection criteria for STREXIT 2\n\n   * Patients with histologically proven primary resectable localized high-risk DDLPS or LMS of retroperitoneal space or infra-peritoneal spaces of pelvis (as described in the inclusion criteria of STRASS 2) and amenable to receive chemotherapy but for whom the list of eligibility criteria for the study is too restrictive (tumour grading not available, inadequate organ function, concomitant diseases)\n   * Patients who meet all eligibility criteria of STRASS 2 but do not consent to randomization or are not enrolled for any other reason.\n   * Patients enrolled in a Registry collecting data on primary RPS patients in the centres participating in STRASS 2 (e.g., RESAR) and who satisfy the above criteria.\n3. Selection criteria for preferences for neoadjuvant chemotherapy in STRASS 2 substudy\n\nAll patients recruited to STRASS 2 in participating centres (Australia +\u002F- international sites) that are able to read, comprehend and write in English at a sufficient level to complete study materials.",{"count":605,"type":22},250,[64],"This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.\n\nAfter confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.",[609,610,611],"Retroperitoneal Sarcoma","Liposarcoma","Leiomyosarcoma",{"date":613,"type":43},"2026-05-22",{"date":615,"type":43},"2021-01-20",{"date":617,"type":22},"2028-04-21",{"name":139,"class":140},169,{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":17,"sex":18,"minAge":440,"maxAge":550,"enrollmentInfo":627,"targetDuration":4,"studyType":23,"phases":629,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":51},"100588009","comparison-of-the-effects-of-bimanual-finger-and-vr-exercises-in-pwmci-100588009","NCT06935812","Comparison of the Effects of Bimanual, Finger and VR Exercises in PwMCI","Comparison of the Effects of Bimanual, Finger and Virtual Reality Exercises in Individuals With Mild Cognitive Impairment - Randomized Controlled Study","Inclusion Criteria:\n\n* Participants who are between 50-75 years of age\n* Individuals diagnosed with MCI by a geriatrician according to DSM-5 criteria,\n* Who has the Montreal Cognitive Assessment score between 13-26,\n* Who has the Quick Mild Cognitive Impairment screen score between 48-67,\n* Who has Instrumental Activities of Daily Living Scale score ≥6\u002F8,\n* Who says yes to \"Do you have a memory problem?\" question,\n* Who can walk independently without using any walking aids\n\nExclusion Criteria:\n\n* Participants who have any musculoskeletal disorders that may cause balance and gait disorders,\n* Who have central or peripheral neurological diseases (eg. stroke, Parkinson's disease or polyneuropathies),\n* Who are using psychiatric drugs that may affect psychiatric disease and\u002For cognitive performance (Using nonsteroidal anti-inflammatory drugs more than three times a week, which may affect cognitive functions, using gingko biloba and antioxidant supplements (for example, coenzyme Q10 and alpha-lipoic acid)),\n* Who has daltonism and\n* Who attends any exercise program last 6 months will not be included in this study.",{"count":628,"type":22},106,[25],"Mild Cognitive Impairment (MCI) is defined as an impairment in a single cognitive function, usually memory, other than normal cognitive decline with age, that does not fulfil dementia criteria. Finger movements have been shown to stimulate the sensory-motor and cognitive parts of the cerebral cortex, as well as the supplementary motor area, Broca's area, premotor cortex, and prefrontal cortex, all of which contribute to movement skills. Asymmetrical hand and finger movements done concurrently were proven to improve cognitive processes and cerebral blood flow more than movements performed with one hand.",[632],"Mild Cognitive Impairment",[634,635,636,637,638,639,640,641,642],"Finger Exercise","Bimanual Exercise","Virtual Reality","Processing Speed","Cognitive Functions","Walking Speed","Gross Motor Skills","Fine Motor Skills","Dual Task","2026-05-17",{"date":645,"type":43},"2026-05-19",{"date":647,"type":43},"2025-04-29",{"date":649,"type":22},"2026-09-24",{"name":49,"class":50},{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":18,"minAge":339,"maxAge":658,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":677,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":51},"100592604","dietary-supplements-in-patients-with-coronary-artery-bypass-grafting-for-improving-the-quality-of-healthcare-delivery-100592604","NCT06995586","Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","Inclusion Criteria:\n\n* The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).\n* Signed consent form\n* Ability to adhere to the protocol\n\nExclusion Criteria:\n\n* Any psychiatric, neurological or motor disorder.\n* Hypersensitivity to the components of the supplement.\n* Combined Cardiac Surgery other than CABG and valve or aortic\n* Concurrent participation in other clinical trials.\n* Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and\u002For Omega 3 fatty acids.","80 Years",{"count":660,"type":22},108,[25],"Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) and Omega 3 fatty acids, Eicosapentaenoic \u002F Docosahexaenoic Acid (EPO\u002FDHA), powerful but also necessary antioxidants for the human body, after observational studies as well as randomized studies seem to have a beneficial effect in the direction of the prevention of CVD with pleiotropic mechanisms. Lignin, a polymer of plant origin that is considered a dietary fiber, has a developed porous structure and can retain exogenous and endogenous toxins, and pathogenic microorganisms. Lactulose considered a prebiotic provides a selective substrate for the metabolism of saccharolytic bacteria with bifidogenic activity and multiple benefits to the host's gut health. Coronary artery bypass grafting (CABG) is an established surgical intervention and treatment of symptoms of myocardial ischemia that improves patient survival Optimal Medical Therapy (OMT) after coronary arterial bypass grafting (CABG) as described in current clinical practice could be made even better by the addition of these beneficial food supplements.\n\nA randomized controlled trial is proposed in an intervention group of 54 post-CABG patients who will be given daily orally in addition to the usual medication, 1000 mg Vitamin C, 840 mg EPO\u002FDHA, 2130 mg Lignin \\& 720 mg Lactulose and a control group of 54 patients (Control Group) in which only usual medication will be administered. The intervention will take place from the 15th postoperative day when CAGB patients are discharged and lasts for 2.5 months (10 weeks) postoperatively. The data will be collected on the 15th, 80-90th postop day in 6 months and 12 months postop and then the statistical analysis of the data will be performed. Considering the number of CABG surgeries performed electively in our clinic, this study is expected to be completed in approximately 2-3 years from the day of initiation.\n\nThe expected knowledge through the expected results such as these will emerge from this study is the potentially beneficial effect of our food supplements administration (intervention), i.e. Vitamin C, EPO\u002FDHA, Lignin \\& Lactulose, on the postoperative course of our patients. Some degree of improvement in the well-being and clinical picture of our patients postoperatively is expected, which will be thoroughly investigated in each phase of the study.",[664,155,665,666,667,668,669,670,671,672,673,674,675,676],"Cardio-pulmonary Bypass","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Coronary Artery Bypass Grafting","Prebiotics",[664,155,678,667,670,671,679,668,680,673,674,675,681,682,683,684],"Omega-3 polyunsaturated fatty acids","Omega-3 supplementation","postoperative","postoperative depression","Lignin","adsorbent","prebiotics","2026-05-09",{"date":687,"type":43},"2026-05-13",{"date":689,"type":22},"2026-09-01",{"date":691,"type":22},"2028-12-01",{"name":238,"class":50},{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":698,"acronym":699,"eligibilityCriteria":700,"healthyVolunteers":12,"sex":93,"minAge":19,"maxAge":4,"enrollmentInfo":701,"targetDuration":4,"studyType":23,"phases":702,"briefSummary":703,"conditions":704,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":712,"locationsCount":51},"100636663","comparing-psma-petct-and-mri-rsi-for-finding-and-outlining-tumors-inside-the-prostate-in-men-with-newly-diagnosed-prostate-cancer-100636663","NCT07568613","Comparing PSMA PET\u002FCT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer","Prospective Comparison of PSMA PET\u002FCT and MRI-RSI (Restriction Spectrum Imaging) for Intraprostatic Tumor Detection and Delineation in Primary Prostate Cancer Patients","PRIDE2-PC","Inclusion Criteria:\n\n* Newly diagnosed and histologically confirmed primary prostate cancer\n* NCCNv4.2024 risk groups: unfavorable intermediate risk, high-risk and very high-risk\n* Males, age ≥ 18 years\n* ECOG performance status 0-2\n* Estimated life expectancy ≥ 5 years\n* PSMA-PET\u002FCT-hybrid imaging performed \\\u003C3 months\n* MRI-targeted biopsy on PIRADs v2.1 lesion ≥3 performed \\\u003C6 months\n\nExclusion Criteria:\n\n* Contraindications for MRI imaging\n* No visible tumor on PSMA PET and mpMRI (defined by PIRADs v2.1 ≤2 lesion)\n* TUR-P of the prostate \\\u003C1 year ago\n* Initial PSA \\>100 ng\u002Fml\n* History of cancer (exception: localized skin tumours, tumours treated ≥5 years previously with curative intent and no evidence of recurrent disease)\n* Previous radiation therapy to the pelvis\n* ADT or ADT + other systemic therapy before inclusion",{"count":552,"type":22},[25],"The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer. The current gold standard multiparametric magnetic resonance imaging (mpMRI) is used to guide targeted prostate biopsies for initial diagnostic work up and for definitive focal dose-escalated radiotherapy in intermediate and high-risk prostate cancer patients.\n\nHowever, mpMRI might underestimate the tumor volume and manual gross tumor volume delineation based on mpMRI underlies significant interobserver variability. Thus, novel imaging modalities are warranted to increase the detection rate and\u002For decrease the interobserver variability during tumor delineation.\n\nThis study will prospectively compare two promising advanced medical imaging methods: MRI-RSI and PSMA PET with the current gold-standard mpMRI for tumor detection and delineation in primary prostate cancer patients.",[705],"Prostate Cancer","2026-04-28",{"date":708,"type":43},"2026-05-06",{"date":710,"type":43},"2025-08-18",{"date":514,"type":22},{"name":713,"class":50},"German Oncology Center, Cyprus",{"id":715,"slug":716,"hasResults":12,"nctId":717,"briefTitle":718,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":721,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":723,"conditions":724,"keywords":4,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":729,"completionDateStruct":730,"leadSponsor":732,"locationsCount":734},"100634884","ablative-therapy-of-oligometastatic-tumor-after-response-to-conventional-first-line-treatment-100634884","NCT07545486","Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment","ATOM-1st","Inclusion Criteria:\n\n1. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG).\n2. Histologically diagnosis of one of these tumour types:\n\n   1. Hormone receptor positive, HER2 negative breast cancer\n   2. Triple negative breast cancer\n   3. HER2+ breast cancer\n   4. Non small cell lung cancer without oncogenic addiction\n   5. Head and Neck squamous cell carcinoma without recurrence in the radiation field\n   6. Gastric adenocarcinoma\n   7. Esophageal cancer (adenocarcinoma or epidermoid carcinoma)\n   8. Recurrent pancreatic cancer without local recurrence\n   9. Anal cancer\n   10. Bladder cancer\n   11. Clear cells renal cell carcinoma\n   12. Prostate cancer sensitive to castration\n   13. Adenocarcinoma endometrial cancer\n   14. Epidermoid carcinoma or adenocarcinoma of the cervix\n   15. Colorectal cancer\n   16. Recurrent Soft Tissue Sarcoma\n   17. Melanoma\n3. Patient with a decision by the local team to give OST and effective administration of OST. OST is defined as the most efficient choice in terms of survival in first line of advanced disease according to ESMO or other international guidelines. In case of multiple choice as first line, if no data provided direct evidence of superiority from one or the other options, there are all considered as OST. If the patient received a less efficient treatment because of his comorbidity or frailty, the eligible criteria won't be fulfilled.\n4. Have non-progressive disease after 3 to 6 months of treatment, and less than 6 weeks before presentation to the multidisciplinary team\n\n   1. Patients with complete response and no target lesion are excluded.\n   2. Patients with bone metastasis with remaining bone condensation or scare from tumoral activity may be eligible depending on metabolic activity of the lesion or local multidisciplinary committee decision concerning the risk of residual disease.\n5. After 3 to 6 months of treatment, and less than 6 weeks before start of LAT, patient must have an oligometastatic disease defined as all lesions (including primitive lesion) amenable to local ablative treatment according to local investigator team and respective local committee.\n\nExclusion Criteria:\n\n1. Patients who already received systemic antitumoral treatment in the advanced setting (including chemotherapy, immunotherapy, targeted therapy, …)\n2. Patients without OST administration\n3. Patients that have progressing lesion at any time point before decision of LAT by the expert committee\n4. Has a known recent history of other invasive tumour, excepted if local investigator may provide histologically data that all active lesions targeted are from the same cancer primitive.\n5. Radiotherapy or other LAT to any metastatic site before the start of OST.\n6. Exclusion criteria specific for France: Vulnerable persons according to the article L.1121-6 of the public health law (CSP), adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP",{"count":722,"type":22},1235,"Advancements in systemic antineoplastic therapies have led to improved overall survival rates for many solid tumors. However, metastatic disease remains a significant challenge and remains the leading cause of mortality for these patients. Additionally, there is a high attrition rate after first-line standard treatment across various tumor types, with studies indicating that 20-70% of patients may be unable to undergo second-line therapy, depending on the tumor type.\n\nThis highlights an urgent need to enhance outcomes from the first line of treatment. Although first-line therapy often represents the best available option, most patients experience relapse and disease progression despite an initial tumor response. This is attributed to both intrinsic and acquired resistance arising from the heterogeneity of primary tumors and metastases. To address this issue, metastasis-directed therapy (MDT) has been explored as a way to reduce tumor burden and mitigate the risk of resistance due to therapeutic selective pressure.\n\nMDT offers a promising opportunity to improve first-line treatment outcomes, but more precise patient selection criteria are needed to maximize therapeutic benefit and minimize the potential toxicity of ablative therapies. Indeed, despites its efficacy, fatal complication may occur so do grade 3 to 4 toxicities. Toxicity depends of the local ablative therapy (LAT) planned but as it will never be none, oncologists have to propose invasive treatment to patient that may benefit the most.\n\nBased on the published data, the investigators propose a pragmatic, selective approach centered on sensitivity to systemic therapy. The investigators aim to evaluate the benefit of local ablative therapy (LAT) in patients who demonstrate non-progressive disease after three months of first-line standard of care. Given the importance of this question across cancer subtypes, the investigators will employ a prospective database to enroll patients with various solid tumor type, excluding the ones for which the impact of LAT has already been explored or may be difficult to achieve. Outcomes of this strategy will be evaluated compared to outcomes from pivotal studies defining optimal standard first line therapy (OST) .\n\nSeveral analyses will be performed to better characterize the population for whom a multimodal approach may significantly improve their survival. The first one will aim to compare the median duration of response (mDOR) of the population treated with LAT compared to the mDOR reported by the pivotal study(ies) of each OST.\n\nThis study will serve as a proof of concept, supporting chemosensitivity as a viable selection factor for multimodal treatment in a broad range of cancer types.\n\nPrimary objective:\n\nImprovement of the duration of response (DOR) after completion of LAT compared to DOR reported in pivotal study that evaluated first line OST.\n\nSecondary objectives:\n\n* Evaluation of the safety of the addition of LAT.\n* Evaluation of overall progression free survival (PFS) and PFS at 1 year.\n* Evaluation of overall survival from OST start and from the time of LAT completion.\n* Documentation of acceptance and compliance to LAT decision by the institutional expert committee",[725],"Solid Tumor","2026-04-21",{"date":728,"type":43},"2026-04-22",{"date":561,"type":22},{"date":731,"type":22},"2036-06-01",{"name":733,"class":50},"Chirec",12,{"id":736,"slug":737,"hasResults":12,"nctId":738,"briefTitle":739,"officialTitle":740,"acronym":4,"eligibilityCriteria":741,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":742,"targetDuration":4,"studyType":23,"phases":743,"briefSummary":744,"conditions":745,"keywords":4,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":749,"lastUpdatePostDateStruct":750,"startDateStruct":752,"completionDateStruct":754,"leadSponsor":756,"locationsCount":51},"100635037","the-effect-of-aging-simulation-suits-on-nursing-students-attitudes-toward-older-adults-and-their-levels-of-compassion-100635037","NCT07547475","The Effect of Aging Simulation Suits on Nursing Students' Attitudes Toward Older Adults and Their Levels of Compassion","\"The Effect of an Aging Simulation Suit on Nursing Students' Attitudes Toward Older Adults and Their Levels of Compassion Competence: A Randomized Controlled Pretest-Posttest Study\"","Inclusion Criteria:\n\n* Being a third-year nursing student\n* Being enrolled in the HMSR 312 Geriatric Nursing course\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Having a physical condition that would prevent the use of an aging simulation suit\n* Having advanced orthopedic, neurological, or balance problems",{"count":496,"type":22},[25],"With the increasing elderly population, nursing students' attitudes toward older adults and their levels of compassion competence have become increasingly important. While traditional educational methods may be insufficient in developing these skills, experiential learning approaches offer more effective outcomes. In particular, aging simulation applications enable students to understand the physical and emotional challenges experienced by older individuals, thereby enhancing their levels of empathy and compassion. The literature reports that simulation-based education has positive effects on attitudes and awareness. Therefore, the integration of aging simulation suits into nursing education is of great importance.",[746,747,748],"Ethics","Aging","Compassion","2026-04-16",{"date":751,"type":43},"2026-04-23",{"date":753,"type":22},"2026-04-25",{"date":755,"type":22},"2026-06-25",{"name":49,"class":50},""]